Epidermodysplasia verruciformis: successful treatment with squaric acid dibutylester.

Epidermodysplasia verruciformis (EV) is a rare disorder characterized by disseminated cutaneous warts in predisposed patients who are highly susceptible to genus ß-papillomavirus infections. We present the case of a 40-year-old lymphocytopenic woman with a balanced chromosomal translocation and a 25-year history of refractory EV that was successfully treated with squaric acid dibutylester (SADBE) contact immunotherapy.

[1]  V. Mahajan,et al.  Autosomal dominant epidermodysplasia verruciformis: a clinicotherapeutic experience in two cases. , 2010, Indian journal of dermatology, venereology and leprology.

[2]  M. Pawlita,et al.  Seroreactivity of 38 human papillomavirus types in epidermodysplasia verruciformis patients, relatives, and controls. , 2010, The Journal of investigative dermatology.

[3]  S. Yamazaki,et al.  Usefulness of topical immunotherapy with squaric acid dibutylester for refractory common warts on the face and neck , 2009, The Journal of dermatology.

[4]  R. Robati,et al.  Four familial cases of epidermodysplasia verruciformis: mother and three sons. , 2009, Dermatology online journal.

[5]  M. Pawlita,et al.  High beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis. , 2009, The Journal of investigative dermatology.

[6]  A. Bruckner,et al.  Epidermodysplasia verruciform-like Lesions in an HIV patient. , 2009, Dermatology online journal.

[7]  G. Papatheodorou,et al.  Systemic low‐dose isotretinoin maintains remission status in epidermodysplasia verruciformis , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  Yan Wang,et al.  Epidermodysplasia Verruciformis with severe hand and foot deformity successfully treated with surgical excision. , 2008, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[9]  G. Cappellano,et al.  Identification of defective Fas function and variation of the perforin gene in an epidermodysplasia verruciformis patient lacking EVER1 and EVER2 mutations. , 2008, The Journal of investigative dermatology.

[10]  W. Huang,et al.  Successful Treatment of Recalcitrant Warts with Topical Squaric Acid in Immunosuppressed Child , 2008, Pediatric dermatology.

[11]  U. Gul,et al.  Epidermodysplasia verruciformis associated with isolated IgM deficiency. , 2007, Indian journal of dermatology, venereology and leprology.

[12]  V. Prieto,et al.  Common Variable Immunodeficiency Syndrome Associated with Epidermodysplasia Verruciformis , 2007, American journal of clinical dermatology.

[13]  U. Dianzani,et al.  CD8+ T-cell lymphocytopenia and lack of EVER mutations in a patient with clinically and virologically typical epidermodysplasia verruciformis. , 2005, Archives of dermatology.

[14]  S. Holland,et al.  Recurrent ‘sterile’ verrucous cyst abscesses and epidermodysplasia verruciformis‐like eruption associated with idiopathic CD4 lymphopenia , 2003, The British journal of dermatology.

[15]  C. Festa Neto,et al.  Clinical aspects of epidermodysplasia verruciformis , 2003, Journal of the European Academy of Dermatology and Venereology : JEADV.

[16]  S. Majewski,et al.  Epidermodysplasia verruciformis: what's new? , 2003, Journal of the European Academy of Dermatology and Venereology : JEADV.

[17]  N. Ramoz,et al.  Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis , 2002, Nature Genetics.

[18]  P. Lopalco,et al.  Topical immunotherapy with contact sensitizers: a model to study the natural history of delayed hypersensitivity , 2002, Contact dermatitis.

[19]  R. Anadolu,et al.  Treatment of epidermodysplasia verruciformis with a combination of acitretin and interferon alfa-2a. , 2001, Journal of the American Academy of Dermatology.

[20]  G. Micali,et al.  Use of Squaric Acid Dibutylester (SADBE) for Cutaneous Warts in Children , 2000, Pediatric dermatology.

[21]  H. Gollnick,et al.  Successful treatment of disseminated facial verrucae with contact immunotherapy. , 1998, European journal of dermatology : EJD.

[22]  S. Jabłońska,et al.  Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. , 1995, Archives of dermatology.

[23]  G. Orth,et al.  Human papillomavirus (HPV) types specific of epidermodysplasia verruciformis detected in warts induced by HPV3 or HPV3-related types in immunosuppressed patients. , 1992, The Journal of investigative dermatology.

[24]  G. Orth.  Epidermodysplasia verruciformis: a model for understanding the oncogenicity of human papillomaviruses. , 1986, Ciba Foundation symposium.

[25]  D. Lowy,et al.  X-linked inheritance of epidermodysplasia verruciformis. Genetic and virologic studies of a kindred. , 1985, Archives of dermatology.